Canadian perspective on managing multiple myeloma during the COVID-19 pandemic: lessons learned and future considerations

Curr Oncol. 2020 Oct;27(5):270-274. doi: 10.3747/co.27.7149. Epub 2020 Oct 1.

Abstract

The coronavirus disease 2019 (covid-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 has necessitated changes to the way patients with chronic diseases are managed. Given that patients with multiple myeloma are at increased risk of covid-19 infection and related complications, national bodies and experts around the globe have made recommendations for risk mitigation strategies for those vulnerable patients. Understandably, because of the novelty of the virus, many of the proposed risk mitigation strategies have thus far been reactionary and cannot be supported by strong evidence. In this editorial, we highlight some of the risk mitigation strategies implemented at our institutions across Canada during the first wave of covid-19, and we discuss the considerations that should be made when managing patients during the second wave and beyond.

Keywords: Coronavirus; covid-19; multiple myeloma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Betacoronavirus / isolation & purification*
  • COVID-19
  • Canada / epidemiology
  • Coronavirus Infections / complications*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / virology
  • Disease Management
  • Humans
  • Multiple Myeloma / therapy*
  • Multiple Myeloma / virology
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / virology
  • Practice Guidelines as Topic / standards*
  • Risk Management
  • SARS-CoV-2
  • Telemedicine / methods*